Please login to the form below

Not currently logged in
Email:
Password:

Gilead

This page shows the latest Gilead news and features for those working in and with pharma, biotech and healthcare.

Google boosts healthcare business with new hire

Google boosts healthcare business with new hire

Earlier this year, Google’s life science and healthcare division Verily teamed up with Gilead to develop a high-res molecular map of inflammatory diseases.

Latest news

  • Gilead NASH drug clears mid-stage trial, but rivals are looming Gilead NASH drug clears mid-stage trial, but rivals are looming

    Gilead NASH drug clears mid-stage trial, but rivals are looming. Positive results to challenge Intercept in emerging disease area. ... Gilead has positioned GS-9674, a non-bile acid FXR, as having fewer side effects than Ocaliva, particularly pruritus

  • AbbVie sues NHS England over hep C procurement AbbVie sues NHS England over hep C procurement

    The plan was only made possible by enormous strides in the treatment of HCV and in particular new directly-acting antiviral drugs – pioneered by Gilead Sciences with its Sovaldi (sofosbuvir) and ... Gilead was the undisputed leader of the market with

  • GSK’s says depot HIV injection works over three years GSK’s says depot HIV injection works over three years

    GSK’ s says depot HIV injection works over three years. The injection could rival Gilead’s single-tablet therapy. ... The intention is also to keep the company competitive with arch-rival Gilead Sciences, which was the first company to bring a

  • Novartis and Pfizer to collaborate on NASH combinations Novartis and Pfizer to collaborate on NASH combinations

    needs.”. Other companies such as Intercept, Allergan and Gilead have FXR agonists in their pipelines, but Gilead suffered a disappointment when its candidate failed to show efficacy a recent phase 2

  • Novartis claims a rare win at ESMO for PI3K inhibitor class Novartis claims a rare win at ESMO for PI3K inhibitor class

    Zydelig is among the existing PI3K inhibitors on the market. Three PI3K inhibitors have been approved for blood cancers – namely Gilead Sciences’ Zydelig (idelalisib), Bayer’s Aliqopa (copanlisib) and most recently

More from news
Approximately 141 fully matching, plus 336 partially matching documents found.

Latest Intelligence

  • Redefining communications excellence Redefining communications excellence

    Gilead Sciences is among the companies to be lauded for running campaigns that could affect lives. ... Gilead also provided resources to help physicians talk to patients about sexual health.

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    Early signs are looking good: Novartis’Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June

  • The race for an HIV ‘cure’ The race for an HIV ‘cure’

    GSK’s majority-owned ViiV Healthcare is the strongest challenger to Gilead’s 52% market share. ... Gilead has also raised hopes after its candidate GS-9620, which aims to expel the virus from hidden reservoirs, made it through phase 1.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    drugs, Novartis’Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’gene therapy Luxturna all reaching the market last year. ... US prices for Novartis’Kymriah and Gilead’s Yescarta are $475, 000 and $373, 000, respectively, for the

More from intelligence
Approximately 2 fully matching, plus 35 partially matching documents found.

Latest appointments

More from appointments
Approximately 6 fully matching, plus 16 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 18 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics